A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo iā¦ (NCT05976243) | Clinical Trial Compass
Active ā Not RecruitingPhase 3
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
United States362 participantsStarted 2023-12-07
Plain-language summary
This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE).
The purpose of the core period (52 weeks of treatment) of this study is to evaluate the efficacy, safety, and tolerability of remibrutinib (LOU064) vs. placebo in adults suffering from CINDU inadequately controlled by H1-antihistamines (H1-AHs).
The purpose of the OLE period is to collect long-term efficacy, safety, and tolerability data on remibrutinib in participants after having completed the Core period
Who can participate
Age range18 Years ā 100 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Male and female participants ā„18 years of age at the time of signing of the ICFs
ā. Confirmed CINDU diagnosis (as per guidelines) for symptomatic dermographism, cold urticaria or cholinergic urticaria for ā„ 4 months (defined as onset of CINDU with supporting documentation (e.g medical record, clinical history, photographs)) and inadequate control with H1-AH at local label approved doses at the time of randomization
ā. The following response to the provocation test for each subtype is required at the randomization visit :
ā. Cold Urticaria: Positive ice-cube test resulting in hives at the provocation site for participants at Screening.
ā. Cholinergic urticaria: Participants must show sweating in performing the pulse-controlled ergometry test on day of randomization. Participants with anhidrosis must not be included.
ā. Participants who have completed the Core period up to Week 52 and are willing to enter the OLE period
Exclusion criteria
ā. Participants who have concomitant CSU at screening. Participants with resolved CSU at the time of screening can be included in the study.
What they're measuring
1
Proportion of participants with complete response in Total Fric Score; symptomatic dermographism
Timeframe: Week 12
2
Proportion of participants with complete response in critical temperature threshold; cold urticaria
Timeframe: Week 12
3
Proportion of participants with itch numerical rating scale =0; cholinergic urticaria
ā. Participants who have a familial form (e.g familial cold autoinflammatory syndrome, familial cold urticaria) of the target CINDU that is being considered for the participant's inclusion in this study.
ā. Participants having a more defined other form of inducible urticaria than the target CINDU that is being considered for the participant's inclusion in this study.
ā. Diseases, other than chronic inducible urticaria, with urticaria or angioedema symptoms including but not limited to urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa) and hereditary or acquired angioedema
ā. Any other skin disease associated with chronic itching that might influence, in the investigator's opinion, the study evaluations and results (e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, etc.) or skin diseases associated with only wheals and no itch e.g asymptomatic dermographism